Comparison of Lattice Flow Diverter and Pipeline Embolization Device in Unruptured Intracranial Aneurysms: A Real-World, Propensity Score Matching Study

未破裂颅内动脉瘤中 Lattice 血流导向装置与 Pipeline 栓塞装置的比较:一项真实世界倾向评分匹配研究

阅读:3

Abstract

BACKGROUND AND OBJECTIVES: Flow diverters (FDs) have been increasingly used in treating unruptured intracranial aneurysms (UIAs). However, comparative studies between the novel lattice flow diverter (LFD) and other FDs are limited. Our study aimed to compare outcomes of LFD and the pipeline embolization device (PED) for UIAs using propensity score matching (PSM). METHODS: Patients with UIAs treated with LFD or PED between August 2023 and November 2024 were included. PSM was performed to adjust for age, sex, comorbidities, ischemic stroke history, smoking status, alcohol abuse, preoperative modified Rankin Scale scores, history of multiple aneurysms, aneurysm characteristics, adjunctive coiling, and angiographic follow-up duration. Perioperative complications and clinical and angiographic outcomes were compared after matching. RESULTS: A total of 99 patients treated by LFD and 187 patients treated by PED were included. Compared with the PED group, the LFD group had fewer females and more patients with a history of multiple aneurysms, wider aneurysm necks, shorter stent lengths, and lower rates of in-stent stenosis (ISS) (stenosis > 50%). After PSM, 55 matched pairs were analyzed. The LFD group demonstrated significantly lower ISS rates (1.8% vs 14.5%, P = .037), with no significant differences in perioperative complications, the complete occlusion rate at the median 216-day angiographic follow-up (87.3% vs 85.5%, P > .999), or favorable outcomes (96.4% vs 94.5%, P > .999) compared with the PED group. CONCLUSION: The mechanical balloon-based LFD with surface modification showed a lower ISS rate and comparable perioperative outcomes, short-term occlusion rates, and clinical prognosis compared with PED. The advantages brought by the Innovation of LFD warrant further validation through long-term randomized controlled trials.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。